Related Experiment Videos
Progesterone-induced urticaria: response to buserelin
1Department of Dermatology, Leeds General Infirmary, U.K.
The British Journal of Dermatology
|January 1, 1994
Summary
This study presents a case of cyclical urticaria successfully treated with buserelin, a gonadotropin-releasing hormone analogue. This offers a new therapeutic option for progesterone-induced urticaria when other treatments fail.
Area of Science:
- Reproductive Endocrinology
- Dermatology
- Hepatology
Background:
- Cyclical urticaria linked to menstrual cycles presents a treatment challenge.
- Standard antihistamines and hormone therapies may not effectively manage severe cases.
- Polycystic liver and kidney disease can complicate treatment options.
Observation:
- A 41-year-old woman with polycystic liver and kidney disease experienced severe cyclical urticaria.
- Her urticaria was refractory to antihistamines and conjugated oestrogens/norgestrel.
- Intradermal progesterone testing yielded a strong positive reaction.
Findings:
- Intranasal buserelin, a GnRH analogue, effectively controlled the patient's urticaria within 4 weeks.
- Symptomatic relief was sustained for 6 months prior to the patient's death from unrelated complications.
- Buserelin induced amenorrhea and hot flushes as side effects.
Implications:
- Buserelin demonstrates potential as a treatment for progesterone-induced urticaria.
- It may be a valuable alternative for patients with contraindications to or poor response from conjugated oestrogens.
- This case highlights the role of hormonal modulation in managing specific urticarial conditions.